Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arixa Pharmaceuticals Inc.

www.arixapharma.com

Latest From Arixa Pharmaceuticals Inc.

Arix Taps Australia's 'Undervalued' Pharmaxis As First VIPE, More Planned

UK-listed Arix completed its first Venture Investment in Public Equity (VIPE), leading a A$24m (£13.4m) investment in Australian biotech Pharmaxis.

Financing Business Strategies

Venture Funding Deals: Two Companies With China Ties Raise $260m Each

Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.

Deals Financing

Evotec And Arix Bridge Gap With Latest Cancer Funding

Arix Biosciences and Evotec AG have formed an academic partnership to accelerate research discoveries at the Fred Hutchison Cancer Research Center.

Research & Development Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arixa Pharmaceuticals Inc.
  • Senior Management
  • John Freund, MD, CEO
    Eric Gordon, CSO
  • Contact Info
  • Arixa Pharmaceuticals Inc.
    Palo Alto, CA
    USA
UsernamePublicRestriction

Register